CNBC's Jim Cramer on Tuesday outlined a simple framework to make sense of the current market, as the threat of artificial intelligence disruption looms over industries from software to commercial real estate. "We want companies that make things and do stuff that we can understand. We want to avoid stuff we can't or don't comprehend, because if you can't get your head around it, then it's probably the kind of stock that Anthropic ... can wreck with a simple press release," Cramer said on "Mad Money," referen ...

Keytruda's been driving Merck's growth for nearly a decade, accounting for almost half of the company's total sales last year. But new US federal drug pricing policies will bring lower-priced competitors into the market within the next few years. The drug giant has been working hard to diversify its pipeline and has some promising new treatments, including a more effective pneumonia vaccine Capvaxive and a novel lung disease treatment Winrevair.To help the performance of its new products stand out, Merck w ...

The Dow Jones Industrial Average (^DJI) was down 821.91 (-1.66%) points today, as the index retreated to 48,804.06. While Dow Futures (YM=F) was up 126.00 (+0.26%), the spot market struggled under the weight of significant losses in the technology and financial sectors. The dominant narrative was a sharp correction in enterprise tech sentiment following a major decline in IBM (IBM), coupled with renewed fears regarding consumer credit health that battered payment processors and major banks.The primary catal ...

Group 1 - Johnson & Johnson is preparing for a potential sale of its orthopedics unit, DePuy Synthes, as part of its plan to separate the business, targeting completion within 18 to 24 months [1] - The company acquired DePuy Synthes in 2011 for $21.3 billion and aims to enhance strategic and operational focus through this separation [1] - Bank of America analysts believe that the exit makes sense and that DePuy Synthes could benefit from improved focus and competitiveness [3] Group 2 - The unit is estimated to be worth about $20 billion, or $28 billion including debt, with interest from buyout firms and potential strategic medical device players [3][5] - Johnson & Johnson is preparing financial materials for meetings with potential buyers in the coming weeks, with several large private equity firms considering joint bids [4] - DePuy Synthes generated $9.3 billion in annual sales, producing hip and knee replacement devices, which may attract further interest [5] Group 3 - Johnson & Johnson reported a fourth-quarter 2025 adjusted earnings of $2.46 per share, a 20.6% increase year over year, surpassing the consensus estimate of $2.44 [6] - The company expects 2026 sales to be between $99.50 billion and $100.5 billion, compared to the consensus of $98.89 billion [6]

The Dow Jones Industrial Average (^DJI) was down 821.91 (-1.66%) points today, closing at 48,804.06, while Dow Futures (YM=F) fell 857.00 (-1.73%) to 48,817.00. The main narrative driving the market was a sudden 15% blanket tariff announcement, which reignited trade war fears and global economic uncertainty. This policy shift, combined with hawkish Federal Reserve commentary suggesting a "coin flip" for future rate cuts, triggered a massive rotation out of cyclical and growth sectors into defensive assets.F ...

Transaction expected to be accretive to earnings per share from 2028 onwards.Deal provides full control of anito-cel, an investigational CAR-T therapy for multiple myeloma.Gilead Moves Into CAR-T Oncology With Arcellx AcquisitionGilead Sciences just made a big move, announcing a $7.8 billion deal to buy Arcellx. It’s their biggest acquisition since 2020, signaling they’re serious about moving beyond just HIV and liver disease treatments.Arcellx shares shot up right after the news. Gilead’s offering $115 per ...

The Dow Jones Industrial Average (^DJI) was down 798.40 (-1.61%) points today, currently sitting at 48,827.57. Similarly, Dow Futures (YM=F) was down 742.00 (-1.49%) points. The primary narrative driving this sharp decline was a significant "risk-off" rotation triggered by renewed concerns over stubborn inflation data and a potential hawkish shift in monetary policy. This sentiment disproportionately affected the financial and technology sectors, as investors moved capital away from growth-oriented and cred ...

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard. Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences. At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000 ...

The Dow Jones Industrial Average (^DJI) was down 715.91 (-1.44%) points today, reaching 48,910.06, while Dow Futures (YM=F) was down 740.00 (-1.49%) points. The primary narrative driving the market lower is a sharp retreat in the financial and technology sectors, sparked by a hawkish shift in monetary policy expectations and rising concerns over consumer credit health. Investors are rotating out of cyclical names in favor of defensive havens as economic uncertainty regarding interest rate trajectories for t ...

Skip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivBayer files lawsuit against Johnson & Johnson, Janssen BiotechFebruary 23, 20263:43 PM UTCUpdated agoBy ReutersThe 120 metres high Bayer Cross, logo of German pharmaceutical and chemical maker Bayer AG, consisting of 1710 LED glass bulbs is seen outside the industrial park "Chempark" of the chemical... Purchase Licensing Rights, opens new tab Read moreCompaniesBayer AGJanssen Biotech IncJohnson ...